Geneva, Switzerland, December 18, 2019.

Abologix has received recognition in “Bilan” as one of the most promising swiss start-ups in the french speaking cantons of Switzerland. The company has been invited to address a group of potential investors in a future meeting to be held in Lausanne, Switzerland.

About Abologix Abologix is a pre-clinical stage biopharmaceutical companydeveloping best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule JAM-C and the extracellular matrix-related protein Olfactomedin-like protein 3 (Olfml3)for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Genevaand the Hôpitaux Universitaires de Genève.

Geneva, Switzerland, July 24, 2019

Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model.

In this study the efficacy of rH225 was tested by assessing:

  1. the delayed mortality upon Jeko-1 MCL cell injection and

  2. the reduction of Jeko-1 cells burden in the blood, spleen, lymph nodes, bone marrow and liver

rH225 delayed significantly the body weight loss and the onset of clinical disease signs in mice inoculated with Jeko-1 MCL cells. Survival of mice was significantly improved.

Splenomegaly was observed in control antibody-treated animals, but not in rH225-treated mice, suggesting that the treatment effectively prevented spleen infiltration by Jeko-1 cells. Indeed, flow cytometry data revealed that treatment with rH225 significantly decreased the Jeko-1 burden in the spleen, liver, lymph nodes, blood and blood marrow.

“We are very pleased that antibody rH225blocked infiltration in all lymphoid organs as well as in bone marrow. Inhibiting access of tumour cells to survival niches constitutes a potential new strategy for lymphoma treatment”

said Prof. Beat Imhof and Prof. Thomas Matthes, scientific co-founders of Abologix.

Geneva, Switzerland, September 5, 2018

Abologix has been selected to enter Fondation Eclosion, the Geneva Life Sciences incubator supported by the Republique et canton de Genève. Under the program Abologix will receive invaluable business, scientific and financial support.

“We are honoured and grateful to have been selected to participate in this incubation program. This will allow the company to access critical resources required for its growth. We hope to make a lasting contribution to the growth of the biotechnology ecosystem in the city of Geneva”

said Ignacio Faus, co-founder and Chairman of the Board of Abologix.

Copyright © 2021 ABOLOGIX